title: Cocktail therapy for hip necrosis in SARS patients.
abstract: BACKGROUND
  There are no treatment guidelines for hip necrosis in severe acute respiratory syndrome (SARS) patients. A new regimen of cocktail therapy that consists of extracorporeal shockwave therapy (ESWT), hyperbaric oxygen therapy (HBO) and oral alendronate was utilized in four patients with eight hips. This study evaluated the outcomes of cocktail therapy with a 4-year followup.
  
  
  METHODS
  There were 3 women and 1 man with an average age of 26 +/- 3.8 years. Each hip was treated with 6000 impulses of ESWT at 0.62 mJ/mm2 energy flux density in a single session. Each patient received HBO treatment for 100 sessions and oral alendronate for one year. The evaluations included pain score and Harris hip score, radiographs and magnetic resonance imaging (MRI) of the affected hips.
  
  
  RESULTS
  At the 4-year follow-up, significant improvements in pain score and Harris hip score were observed in all cases (p < 0.001). All patients returned to work as healthcare providers. None required surgical intervention including hip replacement. MRI showed a trend of reduction in bone marrow edema and the size of the lesion, but no changes in the stage of the lesion.
  
  
  CONCLUSIONS
  Cocktail therapy seems promising in delaying the disease progression of SARS-associated femoral head necrosis in the short-term.
authors.affiliation: Department of Orthopedic Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
authors.forename: To
authors.initials: T
authors.lastname: Wong
authors.forename: Ching-Jen
authors.initials: CJ
authors.lastname: Wang
authors.forename: Shan-Lin
authors.initials: SL
authors.lastname: Hsu
authors.forename: Wen-Yi
authors.initials: WY
authors.lastname: Chou
authors.forename: Po-Chun
authors.initials: PC
authors.lastname: Lin
authors.forename: Chung-Cheng
authors.initials: CC
authors.lastname: Huang
mesh_terms: D000328:Adult; D019386:Alendronate / Q000627:therapeutic use*; D005260:Female; D005271:Femur Head Necrosis / Q000000981:diagnostic imaging / Q000628:therapy*; D019220:High-Energy Shock Waves / Q000627:therapeutic use*; D006801:Humans; D006931:Hyperbaric Oxygenation; D008279:Magnetic Resonance Imaging; D008297:Male; D011859:Radiography; D045169:Severe Acute Respiratory Syndrome / Q000150:complications*
chemical_list: D019386:Alendronate